DNA Script said the funds will help the company support expansion and commercialization of its Syntax benchtop DNA printing platform and broaden the portfolio of products powered by enzymatic DNA synthesis technology. The firm has raised a total of $280 million since its inception.

The oversubscribed funding round included participation by new investors Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Farallon Capital, and Moore Strategic Ventures. Existing investors Casdin Capital, LSP, Illumina Ventures, Bpifrance Large Venture Fund, Danaher Life Sciences, Agilent Technologies, M Ventures, Kurma Partners, and Alexandria Venture Investments were also involved in the funding round, according to DNA Script.

Representatives from Coatue and Catalio have joined the company's board as observers.

DNA Script joins Genome Project-write's advisory board
DNA Script has joined the industrial advisory board of Genome Project-write, which has developed a computer-aided design tool for genome design.

DNA Script launches benchtop DNA printer
DNA Script has launched Syntax, a benchtop DNA printer designed for molecular biology and genomics applications. The printer is designed to enable onsite...

DNA Script's benchtop DNA printer to receive final assessment
DNA Script announced it is entering the final phase of evaluation of its Syntax system, a benchtop DNA printer powered by enzymatic synthesis.

DNA Script, Moderna to develop on-demand vaccines, therapeutics
DNA Script and Moderna have announced a partnership to develop on-demand vaccines and therapeutics as part of the U.S. Defense Advanced Research Projects...